NDAORALTABLET
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
8
Data completeness
4/8 — Partial
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYQORZO (aficamten) is an oral small-molecule cardiac myosin inhibitor approved by the FDA in December 2025. It is indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM), a genetic heart condition characterized by abnormal thickening of the heart muscle. Aficamten works by directly inhibiting cardiac myosin, reducing the force of heart contractions and improving cardiac function.
Growth16.1 years to LOE
As a newly launched product in a rare but high-acuity indication with no direct competitors, MYQORZO represents a growth opportunity with expanding team building across commercial, clinical, and supply chain functions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
Started May 2026
40 enrolled
Hypertrophic Cardiomyopathy (HCM)
A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Started Jun 2025
36 enrolled
Obstructive Hypertrophic Cardiomyopathy
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Started May 2024
55 enrolled
PediatricSymptomatic Obstructive Hypertrophic Cardiomyopathy
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
Started Aug 2023
500 enrolled
Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
Started Jun 2023
175 enrolled
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Worked on MYQORZO at Cytokinetics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.